Drainage

Watts Water Technologies Inc. Completes Acquisition of Josam Company

Retrieved on: 
星期二, 一月 2, 2024
Other Energy, Utilities, Oil, Gas, Energy, Other Construction & Property, Residential Building & Real Estate, HVAC, Commercial Building & Real Estate, Other Manufacturing, Construction & Property, Urban Planning, Building Systems, Manufacturing, Hand, Acquisition, Growth, Heat, Drainage, Water quality

Watts Water Technologies, Inc., (NYSE: WTS) (“Watts”) – through its subsidiaries, one of the world’s leading manufacturers and providers of plumbing, heating and water quality products and solutions – today announced that it has completed the previously announced acquisition of Josam Company (“Josam”), a leading provider and manufacturer of drainage and plumbing products for over 100 years.

Key Points: 
  • Watts Water Technologies, Inc., (NYSE: WTS) (“Watts”) – through its subsidiaries, one of the world’s leading manufacturers and providers of plumbing, heating and water quality products and solutions – today announced that it has completed the previously announced acquisition of Josam Company (“Josam”), a leading provider and manufacturer of drainage and plumbing products for over 100 years.
  • The company offers a comprehensive portfolio of high-quality customized products to a diverse customer base serving commercial, industrial, and multi-family end markets.
  • Chief Executive Officer Robert J. Pagano Jr. commented, “We are excited to welcome the Josam team to Watts.
  • I want to thank the teams at Watts and Josam for their efforts to get us to closing today and helping to ensure a smooth, effective transition as we integrate Josam with Watts.”
    Additional information regarding the transaction will be discussed during the Watts fourth quarter earnings call in February 2024.

Human medicines European public assessment report (EPAR): Rhokiinsa, netarsudil, Date of authorisation: 19/11/2019, Revision: 3, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
IOP, Medical Subject Headings, Marketing, Pupil, INN, ATC, Paratriathlon, Bleeding, International, Drainage, Iris, Ocular hypertension, Disease, Language, Brain, Eye, Timolol, European Medicines Agency, Select, Rho, Patient, Vein, Safety, Anatomy, Retina, IIA, Pressure, Optic nerve, Erythema, Medical device

Human medicines European public assessment report (EPAR): Rhokiinsa, netarsudil, Date of authorisation: 19/11/2019, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Rhokiinsa, netarsudil, Date of authorisation: 19/11/2019, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Marketing, Contraindication, INN, Risk, AZA, Nausea, Heart, Inflammation, Disease-modifying antirheumatic drug, Infection, Diagnosis, Risk management, Anatomy, Ulcer, IIA, CHMP, Skin, Sinusitis, ATC, Joint, Pain, Psoriatic arthritis, Drainage, European, Disease, Ageing, Human, Safety, Heart failure, Rheumatoid arthritis, Medical Subject Headings, Agency, European Commission, Immune system, Ulcerative colitis, ACR, International, Arthritis, Language, Blood, Ciclosporin, Viral, Tuberculosis, Select, Patient, Medicine, Methotrexate, Azathioprine, Common, Tumor necrosis factor, Allergy, PUVA, Glycine mollis, Headache, Abdominal pain, Ankylosing spondylitis, Spine, Chronic pain, Committee, DMARD, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Clarity Child Guidance Center Breaks Ground on Vital Renovations to Increase Capacity for Children facing Mental Health Challenges

Retrieved on: 
星期五, 十二月 29, 2023
Walking, Bipolar disorder, Work, Family, Ecosystem, Trauma, Adolescence, Clarity, Depression, Disability, Patient, Drainage, Phase 3, Mental, Numb, Language, Abnormal psychology, SAN, Mental health, Anxiety, Campaign, COVID, Nursing, Housekeeping, Schizophrenia, Suicidal ideation, ADHD, LCSW, Child

SAN ANTONIO, Dec. 29, 2023 /PRNewswire-PRWeb/ -- Clarity Child Guidance Center broke ground during a special ceremony on Wednesday, September 20, 2023, on renovations being made possible through its "HEROES: The Campaign for Clarity." When complete, this $16 million capital campaign will allow Clarity to serve an additional 1,000 kids a year—bringing the annual total to an annual average of 9,000 children and teens--ensuring that every child and family who needs behavioral health services can receive them. Currently, about 60% of children treated at Clarity are uninsured, underinsured or low-income. San Antonio-based Clarity Child Guidance Center--the only nonprofit in South Texas providing a continuum of mental health care for children ages 3-17 and their families to manage conditions ranging from ADHD and anxiety to suicidal ideation, bipolar disorder and/or schizophrenia—is indeed experiencing a 27% increase in inpatient hospitalizations, 19% increase in children who were suicidal, a 65% increase in inpatient treatment of kids that have never been seen in the mental health system before, and a 159% increase in the crisis services department. (More on Clarity below.)

Key Points: 
  • SAN ANTONIO, Dec. 29, 2023 /PRNewswire-PRWeb/ -- Clarity Child Guidance Center broke ground during a special ceremony on Wednesday, September 20, 2023, on renovations being made possible through its "HEROES: The Campaign for Clarity."
  • Currently, about 60% of children treated at Clarity are uninsured, underinsured or low-income.
  • "School violence, isolation of the pandemic, and return to the classroom for the increase in demand.
  • Bexar County Judge Peter Sakai and District 8 Councilman Manny Pelaez publicly reaffirmed their commitment to youth mental health for San Antonio area.

Can golf courses help save the planet? Ask a herd of wild pigs

Retrieved on: 
星期六, 十二月 30, 2023
Irrigation, Water, Bird, Biodiversity, Seed, Bee, Golf, Drainage, Hunting, Nutrient, Rewild, Eye, Housing, COVID, Amphibian, Climate change, Pesticide, Flower, Soil, IMAX

But no, this was not Just Stop Oil back for another round, nor the result of a disgruntled golfer.

Key Points: 
  • But no, this was not Just Stop Oil back for another round, nor the result of a disgruntled golfer.
  • Javelinas (or peccaries) are small but feisty relatives of the domesticated pig, found across the southern US and into South America.
  • A study of wild boar in Spain revealed that they raided golf courses less often during the COVID lockdown, when hunting was curtailed.

The bogey of management

  • But these benefits depend on good management to create a mix of habitats, including flower-filled rough grass, scrub and woodland.
  • Wildlife-friendly golf course management can even benefit the game itself.
  • Water draining from these courses may be polluted with pesticides or nutrients that alter the algae in adjacent streams.
  • French golfers have it easy compared with some of the creatures roaming the fairways in other countries.
  • Florida’s golfers, for example, would do well to keep an eye out for alligators.
  • The Arizona course staff were understandably horrified by the damage done, but the javelinas have their fans too.

Rewild the fairway

  • In the US, the total number of golf courses is declining, with more closures than openings since 2006 – many of them abandoned with no new purpose in mind.
  • Reversing the drainage from derelict courses could create new wetland habitats capable of stalling floods during heavy rainfall.
  • Projects to reverse this damage and rewild golf courses are springing up in England, the US and Australia.
  • The usefulness of pigs and their kin for grubbing up the land is widely recognised in rewilding projects.
  • It has become fashionable among opponents of rewilding to criticise this approach to nature conservation for taking land out of food production.


Don’t have time to read about climate change as much as you’d like?
Get a weekly roundup in your inbox instead. Every Wednesday, The Conversation’s environment editor writes Imagine, a short email that goes a little deeper into just one climate issue. Join the 20,000+ readers who’ve subscribed so far.
Mike Jeffries does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Clínica Camila Samara offers personalized treatments for the body and well-being in Brazil

Retrieved on: 
星期日, 十二月 24, 2023
Woman, Light-emitting diode, Drainage, Environment, Specialization, Skin care, Beauty, Cellulite, Groin, Pregnancy, Massage, Fibrosis, Female, Nursing

Her goal is to offer her clients the best aesthetic treatments, making them feel good about themselves and consequently raising their self-esteem.

Key Points: 
  • Her goal is to offer her clients the best aesthetic treatments, making them feel good about themselves and consequently raising their self-esteem.
  • Camila Samara offers services with cutting-edge technologies to provide customers with unique and personalized experiences.
  • Personalized service Camila Samara works from Monday to Saturday and on one day of the week she offers personalized service at home.
  • This way, I set aside one day a week to serve them “in the comfort of their homes, with more convenience,” said Camila Samara.

ROWEN CELEBRATES MILESTONES ONE YEAR AFTER GROUNDBREAKING

Retrieved on: 
星期四, 十二月 14, 2023
Economic development, Atlanta metropolitan area, Agriculture, University, Drainage, Environment, Education, Emory University, Spelman College, Knowledge, Hall, Medicine, Georgia Gwinnett College, History, Life, Road

Lawrenceville, Ga., Dec. 14, 2023 (GLOBE NEWSWIRE) -- One year ago, the Rowen Foundation hosted its formal groundbreaking and tree-planting ceremony to mark the beginning of Georgia’s first-ever foundation-led knowledge community.

Key Points: 
  • Lawrenceville, Ga., Dec. 14, 2023 (GLOBE NEWSWIRE) -- One year ago, the Rowen Foundation hosted its formal groundbreaking and tree-planting ceremony to mark the beginning of Georgia’s first-ever foundation-led knowledge community.
  • Since then, tremendous progress has been made on the 2,000-acre site, with Phase 1 infrastructure on track for completion in 2024.
  • “Rowen will be pivotal to not only the economic development of Gwinnett, but the state as a whole,” said Partnership Gwinnett Vice President of Economic Development Deven Cason.
  • To learn more about Rowen, see updated renderings of the site and stay up-to-date on the construction progress, please visit rowenlife.com .

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

Retrieved on: 
星期三, 十二月 6, 2023
Fluticasone, Food, Shanda, FDA, PDUFA, Disease, Drainage, Nose, EDS, Polyp (medicine), ENT, MPH, Diagnosis, Patient, Ear, OPTN, Security (finance), Sinusitis, Pharmaceutical industry

YARDLEY, Pa., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the U.S. Food and Drug Administration (FDA) has extended by three months the review period of its supplemental new drug application (sNDA) requesting approval of XHANCE as a treatment for chronic rhinosinusitis. The updated Prescription Drug User Fee Act (PDUFA) goal date is March 16, 2024.

Key Points: 
  • The updated Prescription Drug User Fee Act (PDUFA) goal date is March 16, 2024.
  • On November 15, 2023, as part of the ongoing sNDA review, the FDA requested that Optinose submit additional efficacy subset analyses of existing clinical data from one of the two trials submitted in the sNDA: ReOpen1.
  • On December 4, 2023, the FDA notified Optinose that it will require additional time to review this submission (which the FDA deemed a major amendment), and that the PDUFA goal date would be extended to March 16, 2024.
  • The EDS is designed to uniquely deliver drug high and deep into difficult-to-access sinuses and sinonasal drainage tracts.

Trailbreaker Resources Reports Rock Samples Up to 42.1 g/t Au and 1.93% Cu and Expands Geochemical Trend to 3-Km at Castle Rock Property

Retrieved on: 
星期一, 十一月 27, 2023
Soil, Mount Adam, Anomaly, Watchtower, Flan, Heart, Gold, Drainage, Interpretation, Rare-earth element

Sampling defines a 3 km gold-in-soil trend which includes the Heart zone and newly defined Watchtower and Kokummi zones.

Key Points: 
  • Sampling defines a 3 km gold-in-soil trend which includes the Heart zone and newly defined Watchtower and Kokummi zones.
  • Rock sampling has confirmed historic values at the Flan zone and defined an open gold-in-soil anomaly.
  • Additionally, anomalous moss-mat samples in the southeast and eastern portions of the property have defined new areas of potential mineralization, leading to additional claim staking.
  • Rock and soil geochemical sampling and prospecting successfully defined a three-kilometre gold-in-soil trend with multiple >30 ppb gold anomalies, centered on the previously known Heart showing.

Nordic Pharma Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Completes Acquisition of Visant Medical to Launch Novel Therapy for Dry Eye Disease in the United States

Retrieved on: 
星期一, 十二月 18, 2023
Medical Devices, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, DED, University of Pikeville, OD, FDA, Acquisition, Drainage, Optometry, Professional corporation, MD, University, Associate professor, P.C, Telecanthus, CPT, Patient, Hyaluronic acid, Pharmaceutical industry

Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today the completion of its acquisition of Visant Medical, Inc. (Visant), a leader in medical technology innovation in Dry Eye Disease (DED).

Key Points: 
  • Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today the completion of its acquisition of Visant Medical, Inc. (Visant), a leader in medical technology innovation in Dry Eye Disease (DED).
  • Nordic Pharma will launch and commercialize LACRIFILL in the U.S. and has been chosen because of its focus on Ophthalmology.
  • This acquisition will enhance Nordic Pharma’s impact on the global ophthalmology market starting with the U.S. launch of LACRIFILL, the patented therapy for DED.
  • “Visant is thrilled to be joining the Nordic Pharma group,” said Vartan Ghazarossian, Ph.D., Visant co-founder and CEO.